[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for the three and six months ended June 30, 2022, including the balance sheet, statement of operations, and notes detailing significant accounting policies, a May 2022 PIPE financing, and the Hanmi collaboration agreement [Condensed Consolidated Financial Statements](index=3&type=section&id=Condensed%20Consolidated%20Financial%20Statements) The financial statements show total assets grew to **$222.0 million** by June 30, 2022, with a net loss widening to **$39.7 million** for the first six months, and **$30.8 million** net cash used in operating activities Condensed Consolidated Balance Sheets (in thousands) | | June 30, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $57,203 | $24,027 | | Marketable securities | $150,138 | $165,627 | | Total current assets | $209,929 | $192,973 | | Total assets | $221,996 | $198,636 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $13,146 | $9,595 | | Total liabilities | $19,863 | $12,256 | | Total stockholders' equity | $202,133 | $186,380 | Condensed Consolidated Statements of Operations (in thousands, except per share data) | | Three Months Ended June 30, | Six Months Ended June 30, | | :--- | :--- | :--- | :--- | :--- | | | **2022** | **2021** | **2022** | **2021** | | Revenue | $886 | $869 | $1,527 | $2,091 | | Research and development | $14,359 | $13,190 | $31,029 | $26,961 | | General and administrative | $5,436 | $3,760 | $10,184 | $7,772 | | Net loss | $(19,184) | $(16,110) | $(39,652) | $(32,624) | | Net loss per share, basic and diluted | $(0.62) | $(0.63) | $(1.31) | $(1.29) | Condensed Consolidated Statements of Cash Flows (in thousands) | | Six Months Ended June 30, | | :--- | :--- | :--- | | | **2022** | **2021** | | Net cash used in operating activities | $(30,773) | $(27,826) | | Net cash provided by (used in) investing activities | $13,379 | $(51,281) | | Net cash provided by financing activities | $50,570 | $140,409 | | Net increase in cash and cash equivalents | $33,176 | $61,302 | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the May 2022 PIPE financing, which generated **$49.8 million** in net proceeds, along with **$1.5 million** in Hanmi collaboration revenue and **$5.4 million** in stock-based compensation expense for the six months ended June 30, 2022 - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule therapies for inflammatory diseases and oncology[19](index=19&type=chunk) - In May 2022, the company completed a private investment in public equity (PIPE) financing, selling pre-funded warrants to purchase **4,000,000 shares** of common stock, resulting in net proceeds of approximately **$49.8 million**[21](index=21&type=chunk)[60](index=60&type=chunk) - Revenue recognized from the Hanmi Agreement was **$1.5 million** for the six months ended June 30, 2022. As of this date, the performance obligation was substantially complete, and there was no remaining deferred revenue[58](index=58&type=chunk) Stock-based Compensation Expense (in thousands) | | For the Three Months Ended June 30, | For the Six Months Ended June 30, | | :--- | :--- | :--- | :--- | :--- | | | **2022** | **2021** | **2022** | **2021** | | Research and development | $1,269 | $1,627 | $2,448 | $3,101 | | General and administrative | $1,403 | $1,261 | $2,926 | $2,474 | | **Total** | **$2,672** | **$2,888** | **$5,374** | **$5,575** | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=16&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses operational progress, including the RPT193 Phase 2b trial, and financial results showing a net loss of **$39.7 million** for the first six months of 2022, with **$207.3 million** in cash and marketable securities deemed sufficient for the next 12 months [Overview](index=16&type=section&id=Overview) RAPT, a clinical-stage biopharmaceutical company, initiated a Phase 2b trial for RPT193 in May 2022, and has an accumulated deficit of **$323.7 million** as of June 30, 2022, expecting substantial future expenditures - The company's two lead drug candidates, RPT193 (inflammatory diseases) and FLX475 (oncology), both target C-C motif chemokine receptor 4 (CCR4)[70](index=70&type=chunk) - In May 2022, the company initiated a 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to evaluate RPT193 in patients with moderate-to-severe atopic dermatitis (AD)[72](index=72&type=chunk) - As of June 30, 2022, the company had an accumulated deficit of **$323.7 million** and believes its cash and marketable securities of **$207.3 million** will be sufficient to fund planned operations for at least **12 months**[73](index=73&type=chunk)[74](index=74&type=chunk) [Results of Operations](index=19&type=section&id=Results%20of%20Operations) For the six months ended June 30, 2022, revenue decreased to **$1.5 million**, R&D expenses increased **15%** to **$31.0 million**, G&A expenses grew **31%** to **$10.2 million**, resulting in a net loss of **$39.7 million** Comparison of Results for the Six Months Ended June 30 (in thousands) | | 2022 | 2021 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Revenue | $1,527 | $2,091 | $(564) | (27)% | | Research and development | $31,029 | $26,961 | $4,068 | 15% | | General and administrative | $10,184 | $7,772 | $2,412 | 31% | | Loss from operations | $(39,686) | $(32,642) | $(7,044) | 22% | | Net loss | $(39,652) | $(32,624) | $(7,028) | 22% | External R&D Expenses by Program (in thousands) | Program | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | | RPT193 | $7,034 | $3,213 | | FLX475 | $6,457 | $7,200 | | Other Programs | $1,187 | $936 | - The **15% increase** in R&D expenses for the first six months of 2022 was primarily driven by a **$3.8 million increase** in development costs for RPT193[97](index=97&type=chunk) [Liquidity and Capital Resources](index=21&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2022, the company held **$207.3 million** in cash and marketable securities, bolstered by **$49.8 million** from a May 2022 PIPE financing, while net cash used in operating activities was **$30.8 million** - The company completed a PIPE financing in May 2022, raising approximately **$49.8 million** in net proceeds[100](index=100&type=chunk) - As of June 30, 2022, the company had cash, cash equivalents, and marketable securities of **$207.3 million** and working capital of **$196.8 million**[100](index=100&type=chunk) Summary of Cash Flows (in thousands) | | Six Months Ended June 30, | | :--- | :--- | :--- | | | **2022** | **2021** | | Net cash used in operating activities | $(30,773) | $(27,826) | | Net cash provided by (used in) investing activities | $13,379 | $(51,281) | | Net cash provided by financing activities | $50,570 | $140,409 | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=23&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is not required to provide this information as it qualifies as a "smaller reporting company" under SEC regulations - As a "smaller reporting company," RAPT Therapeutics is not required to provide quantitative and qualitative disclosures about market risk[112](index=112&type=chunk) [Item 4. Controls and Procedures](index=23&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2022, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of June 30, 2022, the CEO and CFO concluded that the company's disclosure controls and procedures were **effective** at a reasonable assurance level[113](index=113&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[114](index=114&type=chunk) [PART II. OTHER INFORMATION](index=24&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=24&type=section&id=Item%201.%20Legal%20Proceedings) The company states that it is not currently involved in any legal proceedings that are expected to have a material adverse effect on its operations, financial condition, or cash flows - Management believes there are currently no pending legal claims or actions against the company that would have a **material adverse effect** on its results of operations, financial condition, or cash flows[116](index=116&type=chunk) [Item 1A. Risk Factors](index=24&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks, including a history of financial losses, high clinical development failure rates for RPT193 and FLX475, the need for additional funding, reliance on third parties, intense competition, and impacts from global economic instability and the COVID-19 pandemic - The company is a clinical-stage biopharmaceutical firm with a history of losses, an accumulated deficit of **$323.7 million** as of June 30, 2022, and expects to incur significant losses for the foreseeable future[119](index=119&type=chunk) - The company's lead drug candidates, RPT193 and FLX475, are in clinical development, a lengthy, expensive process with an **uncertain outcome**. Failure to demonstrate safety and efficacy could compromise their commercial viability[118](index=118&type=chunk)[121](index=121&type=chunk) - The company will need **substantial additional funds** to advance its drug candidates and cannot guarantee that sufficient capital will be available in the future[118](index=118&type=chunk)[146](index=146&type=chunk) - The ongoing COVID-19 pandemic and unfavorable global economic conditions, including the conflict in Ukraine and inflation, could **materially impact** operations, clinical trials, and the ability to access capital markets[130](index=130&type=chunk)[135](index=135&type=chunk) - The company relies on third parties for manufacturing and conducting clinical trials, creating risks related to supply chain interruptions, quality control, and potential **delays in development programs**[118](index=118&type=chunk)[155](index=155&type=chunk)[161](index=161&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=62&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities, no use of proceeds from registered offerings, and no issuer purchases of its equity securities during the reporting period - There were **no unregistered sales** of equity securities, use of proceeds, or issuer purchases of equity securities during the quarter[289](index=289&type=chunk) [Item 6. Exhibits](index=63&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including the Securities Purchase Agreement, Registration Rights Agreement for the May 2022 financing, and officer certifications - The report includes an index of exhibits filed, which incorporates by reference key documents such as the Amended and Restated Certificate of Incorporation, agreements related to the May 2022 PIPE financing, and required officer certifications[294](index=294&type=chunk)[295](index=295&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Therapeutics, Inc. (Registrant's telephone number, including area code) (Exact name of registrant as specified in it ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...

Transforming the Treatment of Cancer and Inflammation November 2021 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete ce ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3313701 (State or other ju ...

Transforming the Treatment of Cancer and Inflammation September 2021 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete c ...

Clinical safety and efficacy of RPT193, an oral CCR4 inhibitor: Results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to- severe atopic dermatitis Robert Bissonnette1, Mark Lee2, Janet DuBois3, Joshua Rulloda4, Nadine Lee4, Daniel Johnson4, David Wustrow4, Jasmina Jankicevic4, William Ho4, Laurence Cheng4, Emma Guttman-Yassky5 EADV Late-Breaker Abstract #2746 30 September 2021 1Innovaderm Research Inc., Montreal, Quebec, Canada, 2Progressive Clinical Research, Sa ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) H1 2021 financial position strengthened, total assets doubled to **$231.1 million** from public offering, despite widening net losses and negative operating cash flow [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance sheet shows significant increase in cash and marketable securities, doubling total assets and stockholders' equity by June 30, 2021 Balance Sheet Highlights (in thousands) | Account | June 30, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | Cash and cash equivalents | $86,220 | $24,918 | | Marketable securities | $137,084 | $86,592 | | **Total Assets** | **$231,081** | **$118,969** | | Total Liabilities | $13,502 | $14,790 | | **Total Stockholders' Equity** | **$217,579** | **$104,179** | - Total assets more than doubled from **$119.0 million** at year-end 2020 to **$231.1 million** as of June 30, 2021, driven by increased cash and marketable securities from recent equity financings[11](index=11&type=chunk) [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net losses widened in Q2 and H1 2021, driven by increased R&D and G&A expenses, despite a slight revenue decline Quarterly Operating Results (in thousands, except per share data) | Metric | Q2 2021 | Q2 2020 | | :--- | :--- | :--- | | Revenue | $869 | $1,277 | | Research and development | $13,190 | $10,986 | | General and administrative | $3,760 | $2,802 | | **Net Loss** | **($16,110)** | **($12,387)** | | **Net Loss Per Share** | **($0.63)** | **($0.51)** | Six-Month Operating Results (in thousands, except per share data) | Metric | H1 2021 | H1 2020 | | :--- | :--- | :--- | | Revenue | $2,091 | $2,212 | | Research and development | $26,961 | $21,669 | | General and administrative | $7,772 | $6,091 | | **Net Loss** | **($32,624)** | **($25,526)** | | **Net Loss Per Share** | **($1.29)** | **($1.08)** | - Net loss for Q2 2021 increased to **$16.1 million** from **$12.4 million** in Q2 2020, driven by a **20% increase** in R&D expenses and a **34% increase** in G&A expenses[12](index=12&type=chunk)[78](index=78&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow remained negative, but significant financing activities, primarily from a public offering, led to a substantial net cash increase in H1 2021 Cash Flow Summary for Six Months Ended June 30 (in thousands) | Activity | 2021 | 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | ($27,826) | ($15,172) | | Net cash used in investing activities | ($51,281) | ($103,990) | | Net cash provided by financing activities | $140,409 | $70,736 | | **Net increase (decrease) in cash** | **$61,302** | **($48,426)** | - Financing activities provided **$140.4 million** in cash during H1 2021, primarily from a public offering (**$134.6 million** net) and 'at the market' offerings (**$4.7 million** net), compared to **$70.7 million** in H1 2020[17](index=17&type=chunk)[99](index=99&type=chunk) [Notes to Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail significant H1 2021 equity financings, including a public offering and 'at the market' sales, along with collaboration revenue and stock-based compensation expenses - In June 2021, the company completed a public offering of **4,356,060 shares** of common stock, raising approximately **$134.6 million** in net proceeds[23](index=23&type=chunk) - During H1 2021, the company sold **214,971 shares** through 'at the market' offerings, generating **$4.7 million** in net proceeds[22](index=22&type=chunk) - Revenue from the Hanmi Pharmaceutical collaboration was **$0.9 million** for Q2 and **$2.1 million** for H1 2021, with deferred revenue of **$3.3 million** as of June 30, 2021[52](index=52&type=chunk) - Stock-based compensation expense increased to **$5.6 million** for H1 2021, up from **$4.1 million** in the prior-year period[56](index=56&type=chunk) [Management's Discussion and Analysis (MD&A)](index=14&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) MD&A discusses clinical-stage focus, positive RPT193 trial results, history of losses, **$247.5 million** accumulated deficit, future funding needs despite **$223.3 million** cash from public offering, and rising R&D expenses [Business Overview](index=14&type=section&id=Overview) Clinical-stage biopharmaceutical firm developing oral small molecule therapies for oncology and inflammatory diseases, with positive Phase 1b results for RPT193 in atopic dermatitis - RAPT is a clinical-stage biopharmaceutical company developing oral small molecule therapies for oncology and inflammatory diseases, with lead candidates FLX475 and RPT193 targeting CCR4[61](index=61&type=chunk) - In June 2021, the company announced positive topline results from its Phase 1b trial of RPT193 in patients with moderate-to-severe atopic dermatitis, showing continued improvement at the six-week time point post-treatment[62](index=62&type=chunk) [Results of Operations](index=16&type=section&id=Results%20of%20Operations) Operating results show widening net losses for Q2 and H1 2021, driven by increased R&D and G&A expenses, particularly for FLX475 clinical trials Comparison of Three Months Ended June 30, 2021 and 2020 (in thousands) | Item | Q2 2021 | Q2 2020 | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | $869 | $1,277 | (32)% | | R&D Expenses | $13,190 | $10,986 | 20% | | G&A Expenses | $3,760 | $2,802 | 34% | | **Net Loss** | **($16,110)** | **($12,387)** | **30%** | Comparison of Six Months Ended June 30, 2021 and 2020 (in thousands) | Item | H1 2021 | H1 2020 | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | $2,091 | $2,212 | (5)% | | R&D Expenses | $26,961 | $21,669 | 24% | | G&A Expenses | $7,772 | $6,091 | 28% | | **Net Loss** | **($32,624)** | **($25,526)** | **28%** | - The increase in R&D expenses for both Q2 and H1 was primarily due to higher clinical trial costs related to FLX475, which rose by **$1.3 million** in Q2 and **$2.7 million** in H1 year-over-year[80](index=80&type=chunk)[81](index=81&type=chunk)[87](index=87&type=chunk) [Liquidity and Capital Resources](index=19&type=section&id=Liquidity%20and%20Capital%20Resources%3B%20Plan%20of%20Operations) As of June 30, 2021, the company had **$223.3 million** in cash and equivalents, believes it has sufficient funds for the next 12 months, but acknowledges the need for substantial additional future capital - As of June 30, 2021, the company had cash, cash equivalents, and marketable securities of **$223.3 million** and an accumulated deficit of **$247.5 million**[91](index=91&type=chunk)[64](index=64&type=chunk) - Management believes current cash is sufficient to fund operations for at least the next **12 months** following the report's filing date[91](index=91&type=chunk)[64](index=64&type=chunk) - The company will require substantial additional capital to develop its drug candidates and fund future operations, which it may seek through equity/debt financings or collaborations[92](index=92&type=chunk)[66](index=66&type=chunk) [Controls and Procedures](index=21&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2021, with no material changes to internal control over financial reporting identified - The CEO and CFO concluded that as of June 30, 2021, the company's disclosure controls and procedures were effective at a reasonable assurance level[106](index=106&type=chunk) - No material changes in internal control over financial reporting were identified during the quarter[107](index=107&type=chunk) PART II. OTHER INFORMATION [Risk Factors](index=22&type=section&id=Item%201A.%20Risk%20Factors) Extensive risks include history of losses, uncertain clinical development for FLX475 and RPT193, COVID-19 impacts, reliance on third parties, intense competition, funding needs, IP protection, and regulatory complexities [Business and Financial Risks](index=23&type=section&id=Business%20and%20Financial%20Risks) Key business and financial risks include a history of significant losses, the need for substantial additional funding, and the uncertain, lengthy, and expensive nature of clinical development for lead drug candidates - The company is a clinical-stage biopharmaceutical firm with a history of losses, an accumulated deficit of **$247.5 million** as of June 30, 2021, and expects significant future losses[112](index=112&type=chunk) - Substantial additional funding is required to advance drug candidates, and failure to raise capital on acceptable terms could delay or eliminate R&D programs[137](index=137&type=chunk)[92](index=92&type=chunk) - Lead drug candidates FLX475 and RPT193 are in lengthy, expensive, and uncertain clinical development, where early positive results do not predict future success[114](index=114&type=chunk)[117](index=117&type=chunk) [Operational and Strategic Risks](index=25&type=section&id=Operational%20and%20Strategic%20Risks) Operational risks include potential COVID-19 impacts on trials and supply chains, reliance on sole-source third-party manufacturers and CROs, and intense competition from larger pharmaceutical companies - The COVID-19 pandemic has affected and could continue to impact operations, including slowing clinical trial enrollment and disrupting the supply chain[122](index=122&type=chunk)[125](index=125&type=chunk) - The company relies on third-party manufacturers, some of which are sole-source vendors, for clinical trial supplies, where interruptions could significantly delay development efforts[154](index=154&type=chunk) - The company faces intense competition from large, well-funded pharmaceutical and biotechnology companies with greater resources and experience[160](index=160&type=chunk)[161](index=161&type=chunk)[162](index=162&type=chunk) - The company relies on third-party CROs and clinical investigators to conduct trials, with limited control over their performance, potentially delaying development programs[148](index=148&type=chunk) [Regulatory and Legal Risks](index=36&type=section&id=Regulatory%20and%20Legal%20Risks) Regulatory and legal risks include the lengthy, expensive, and uncertain approval process, ongoing compliance obligations, and potential adverse impacts from healthcare legislative reforms and drug pricing scrutiny - The clinical development and regulatory approval process is lengthy, expensive, and uncertain, potentially preventing U.S. or foreign regulatory approval for drug candidates[230](index=230&type=chunk)[234](index=234&type=chunk) - Approved products face ongoing regulatory obligations, and non-compliance could result in significant penalties or market withdrawal[238](index=238&type=chunk) - Healthcare legislative reform, cost-containment measures, and government scrutiny over drug pricing could adversely affect business and profitability[240](index=240&type=chunk)[243](index=243&type=chunk) [Intellectual Property Risks](index=39&type=section&id=Intellectual%20Property%20Risks) Intellectual property risks involve the costly and uncertain process of obtaining and enforcing patent protection, potential infringement litigation from third parties, and the adequacy of trade secret protection - The company's success depends on obtaining, maintaining, and enforcing patent protection for its technology and drug candidates, an expensive and uncertain process[189](index=189&type=chunk)[190](index=190&type=chunk) - The company may face costly litigation from third parties alleging intellectual property infringement, diverting resources[212](index=212&type=chunk) - The company relies on trade secrets and confidentiality agreements, which may be breached or may not provide adequate protection for proprietary information[223](index=223&type=chunk) [Other Disclosures](index=22&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no material legal proceedings, no unregistered equity sales, and no material change in planned IPO proceeds, with no other significant disclosures under Items 3, 4, or 5 - The company is not currently involved in any legal proceedings that would have a material adverse effect on its financial condition or operations[109](index=109&type=chunk) - There has been no material change in the planned use of proceeds from the company's Initial Public Offering (IPO) as described in its final prospectus[277](index=277&type=chunk)

Transforming the Treatment of Cancer and Inflammation May 2021 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete certain ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3313701 (State or other jurisd ...